BridgeBio Pharma Inc is involved in identifying medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio builds out subsidiary companies around different inherited genetic diseases. The company seeks to translate scientific discoveries from universities, academic medical centers, and pharmaceutical research groups into genetically-targeted therapeutics to address the fundamental causes of diseases. The companies portfolio assets span therapeutic areas, including:
- Genetic dermatology
- Renal disease
Some of the specific indications BridgeBio targets include transthyretin amyloidosis (ATTR-CM and ATTR-PN), pantothenate kinase-associated neurodegeneration, Gorlin syndrome and frequent basal cell carcinomas, dystrophic epidermolysis bullosa, Darier and Hailey-Hailey diseases, Netherton syndrome, venous malformations, Canavan disease, Leber's hereditary optic neuropathy, molybdenum cofactor deficiency Type A, achondroplasia, and FGFR, SHP-2, and K-RAS-drive cancers.
BridgeBio's partners include Leo Pharma, Leidos, Novartis, Cincinnati Children's, Boston Children's Hospital, Takeda, Infinity Pharmaceuticals, NeuroVive Pharmaceutical, St. Jude Children's Research Center, The University of Texas MD Anderson Cancer Center, Spark at Stanford, and University of California San Francisco.